Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog

Maria Alba, Andrew V Schally, Roberto Salvatori

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The proliferation of pituitary somatotroph cells and the synthesis and secretion of GH require the hypothalamic peptide Gil-releasing hormone (GHRH). Accordingly, we have shown that mice with targeted disruption [knockout (KO)] of the GHRH gene (GHRHKO) have isolated GH deficiency (GHD) and anterior pituitary hypoplasia. The weight of GRHRKO mice is about 60% that of normal mice by 12 wk of age. The phenotype is strikingly similar to that observed in the mouse with mutated GHRH receptor (little). It is not known whether exposure to endogenous GHRH during intrauterine growth is necessary for postnatal GH secretion, and whether GHD due to congenital lack of GHRH activity would be reversible by treatment with GHRH during the postnatal period. To answer this question, we treated GHRHKO mice with a long-acting superactive GHRH analog (JI-38) at two ages: from wk 2-6 (2 μg, twice a day) and from wk 12-16 (4 μg, twice a day). Normal littermates served as controls. At both ages JI-38 caused growth acceleration, increase in size of the pituitary gland, increase in pituitary GH mRNA and GH protein levels and serum GH, and significant increase in liver IGF-I mRNA, although none of these parameters was fully normalized. Our findings demonstrate that GHD and pituitary hypoplasia in GHRHKO mice may be partially reversed by long-term treatment with a GHRH analog, and that somatotroph cells maintain responsiveness to GHRH even if this factor is absent during intrauterine development.

Original languageEnglish
Pages (from-to)1506-1513
Number of pages8
JournalEndocrinology
Volume146
Issue number3
DOIs
StatePublished - Mar 1 2005
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Knockout Mice
Growth Hormone
Hormones
Somatotrophs
Pituitary Dwarfism
Messenger RNA
Pituitary Gland
Growth
Insulin-Like Growth Factor I
Blood Proteins
Phenotype
Weights and Measures

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. / Alba, Maria; Schally, Andrew V; Salvatori, Roberto.

In: Endocrinology, Vol. 146, No. 3, 01.03.2005, p. 1506-1513.

Research output: Contribution to journalArticle

@article{62b78bc94faf41d7b7acd753b5a58e0e,
title = "Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog",
abstract = "The proliferation of pituitary somatotroph cells and the synthesis and secretion of GH require the hypothalamic peptide Gil-releasing hormone (GHRH). Accordingly, we have shown that mice with targeted disruption [knockout (KO)] of the GHRH gene (GHRHKO) have isolated GH deficiency (GHD) and anterior pituitary hypoplasia. The weight of GRHRKO mice is about 60{\%} that of normal mice by 12 wk of age. The phenotype is strikingly similar to that observed in the mouse with mutated GHRH receptor (little). It is not known whether exposure to endogenous GHRH during intrauterine growth is necessary for postnatal GH secretion, and whether GHD due to congenital lack of GHRH activity would be reversible by treatment with GHRH during the postnatal period. To answer this question, we treated GHRHKO mice with a long-acting superactive GHRH analog (JI-38) at two ages: from wk 2-6 (2 μg, twice a day) and from wk 12-16 (4 μg, twice a day). Normal littermates served as controls. At both ages JI-38 caused growth acceleration, increase in size of the pituitary gland, increase in pituitary GH mRNA and GH protein levels and serum GH, and significant increase in liver IGF-I mRNA, although none of these parameters was fully normalized. Our findings demonstrate that GHD and pituitary hypoplasia in GHRHKO mice may be partially reversed by long-term treatment with a GHRH analog, and that somatotroph cells maintain responsiveness to GHRH even if this factor is absent during intrauterine development.",
author = "Maria Alba and Schally, {Andrew V} and Roberto Salvatori",
year = "2005",
month = "3",
day = "1",
doi = "10.1210/en.2004-1044",
language = "English",
volume = "146",
pages = "1506--1513",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog

AU - Alba, Maria

AU - Schally, Andrew V

AU - Salvatori, Roberto

PY - 2005/3/1

Y1 - 2005/3/1

N2 - The proliferation of pituitary somatotroph cells and the synthesis and secretion of GH require the hypothalamic peptide Gil-releasing hormone (GHRH). Accordingly, we have shown that mice with targeted disruption [knockout (KO)] of the GHRH gene (GHRHKO) have isolated GH deficiency (GHD) and anterior pituitary hypoplasia. The weight of GRHRKO mice is about 60% that of normal mice by 12 wk of age. The phenotype is strikingly similar to that observed in the mouse with mutated GHRH receptor (little). It is not known whether exposure to endogenous GHRH during intrauterine growth is necessary for postnatal GH secretion, and whether GHD due to congenital lack of GHRH activity would be reversible by treatment with GHRH during the postnatal period. To answer this question, we treated GHRHKO mice with a long-acting superactive GHRH analog (JI-38) at two ages: from wk 2-6 (2 μg, twice a day) and from wk 12-16 (4 μg, twice a day). Normal littermates served as controls. At both ages JI-38 caused growth acceleration, increase in size of the pituitary gland, increase in pituitary GH mRNA and GH protein levels and serum GH, and significant increase in liver IGF-I mRNA, although none of these parameters was fully normalized. Our findings demonstrate that GHD and pituitary hypoplasia in GHRHKO mice may be partially reversed by long-term treatment with a GHRH analog, and that somatotroph cells maintain responsiveness to GHRH even if this factor is absent during intrauterine development.

AB - The proliferation of pituitary somatotroph cells and the synthesis and secretion of GH require the hypothalamic peptide Gil-releasing hormone (GHRH). Accordingly, we have shown that mice with targeted disruption [knockout (KO)] of the GHRH gene (GHRHKO) have isolated GH deficiency (GHD) and anterior pituitary hypoplasia. The weight of GRHRKO mice is about 60% that of normal mice by 12 wk of age. The phenotype is strikingly similar to that observed in the mouse with mutated GHRH receptor (little). It is not known whether exposure to endogenous GHRH during intrauterine growth is necessary for postnatal GH secretion, and whether GHD due to congenital lack of GHRH activity would be reversible by treatment with GHRH during the postnatal period. To answer this question, we treated GHRHKO mice with a long-acting superactive GHRH analog (JI-38) at two ages: from wk 2-6 (2 μg, twice a day) and from wk 12-16 (4 μg, twice a day). Normal littermates served as controls. At both ages JI-38 caused growth acceleration, increase in size of the pituitary gland, increase in pituitary GH mRNA and GH protein levels and serum GH, and significant increase in liver IGF-I mRNA, although none of these parameters was fully normalized. Our findings demonstrate that GHD and pituitary hypoplasia in GHRHKO mice may be partially reversed by long-term treatment with a GHRH analog, and that somatotroph cells maintain responsiveness to GHRH even if this factor is absent during intrauterine development.

UR - http://www.scopus.com/inward/record.url?scp=14244252899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244252899&partnerID=8YFLogxK

U2 - 10.1210/en.2004-1044

DO - 10.1210/en.2004-1044

M3 - Article

C2 - 15564325

AN - SCOPUS:14244252899

VL - 146

SP - 1506

EP - 1513

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 3

ER -